Every record from Janoshik · page 15
The single largest contributor to the index and the de facto reference against which the other five labs are calibrated here. Measured offset against the reference laboratory is 0.000 pp. Full laboratory profile →
| Report | Compound | Supplier | Lot | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041855 | ARA-290 | JEEP | JEEP-2601-K3139 | 2026-Q2 | 99.21 | 4.41 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041614 | GHRP-6 | QSC | QSC-2605-A7936 | 2026-Q2 | 99.93 | 4.48 | 90.2 | Supplier-supplied | 0 | PASS |
| AX-2026-041604 | Enclomiphene citrate | QSC | QSC-2604-R7865 | 2026-Q2 | 99.93 | 4.22 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-041398 | Adipotide | WWB | WWB-2512-R4093 | 2026-Q2 | 98.57 | 2.94 | 105.0 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-043511 | MGF | BCH | BCH-2511-D7240 | 2026-Q2 | 98.69 | 6.01 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043271 | Hexarelin | CPC | CPC-2511-F1491 | 2026-Q2 | 98.35 | 5.33 | 102.6 | Buyer-sourced | 2 | FAIL |
| AX-2026-043092 | Epitalon | KP | KP-2512-R5829 | 2026-Q2 | 98.63 | 6.87 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-042814 | GHRP-6 | GGPeps | GGPE-2605-U1620 | 2026-Q2 | 98.75 | 6.22 | 95.6 | Supplier-supplied | 2 | FAIL |
| AX-2026-042431 | IGF-1 DES (1-3) | SWB | SWB-2601-Y5870 | 2026-Q2 | 98.27 | 4.14 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042283 | Semaglutide | Homopeptide | HOMO-2604-M2254 | 2026-Q2 | 98.50 | 2.58 | — | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042018 | Liraglutide | TFC | TFC-2511-E6528 | 2026-Q2 | 98.29 | 3.61 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041397 | Adipotide | WWB | WWB-2512-R4093 | 2026-Q2 | 98.60 | 3.40 | 90.2 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-043475 | GHRP-6 | WXT | WXT-2604-M5964 | 2026-Q2 | 98.49 | 3.77 | 90.4 | Supplier-supplied | 1 | FAIL |
| AX-2026-043447 | BPC-157 | WXT | WXT-2602-W4680 | 2026-Q2 | 97.34 | 4.43 | 102.2 | Buyer-sourced | 1 | FAIL |
| AX-2026-043085 | Tirzepatide | KP | KP-2605-E6030 | 2026-Q2 | 97.71 | 4.30 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042815 | GHRP-6 | GGPeps | GGPE-2605-U1620 | 2026-Q2 | 97.92 | 6.58 | 93.9 | Buyer-sourced | 1 | FAIL |
| AX-2026-042657 | Semax | GGPeps | GGPE-2512-Y8309 | 2026-Q2 | 99.90 | 7.28 | 103.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042600 | Tirzepatide | GGPeps | GGPE-2604-H8313 | 2026-Q2 | 99.11 | 1.94 | 89.9 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041631 | BPC-157 | QSC | QSC-2511-N8732 | 2026-Q2 | 99.93 | 6.00 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041505 | Kisspeptin-10 | QYB | QYB-2512-X5662 | 2026-Q2 | 99.71 | 4.02 | 100.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043563 | GHRP-6 | BCH | BCH-2603-Y7018 | 2026-Q2 | 98.61 | 4.05 | 106.7 | Supplier-supplied | 1 | FAIL |
| AX-2026-043295 | IGF-1 LR3 | CPC | CPC-2512-S2394 | 2026-Q2 | 97.75 | 2.77 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043277 | Hexarelin | CPC | CPC-2511-F1491 | 2026-Q2 | 98.72 | 5.03 | 95.0 | Supplier-supplied | 2 | FAIL |
| AX-2026-042729 | Survodutide | GGPeps | GGPE-2512-Y9921 | 2026-Q2 | 97.37 | 3.51 | 99.0 | Laboratory-retained | 1 | MARGINAL |
| AX-2026-042617 | KPV | GGPeps | GGPE-2511-K8830 | 2026-Q2 | 97.77 | 4.66 | 93.1 | Buyer-sourced | 1 | FAIL |
| AX-2026-042138 | Hexarelin | Homopeptide | HOMO-2602-R8195 | 2026-Q2 | 99.93 | 4.42 | 95.6 | Supplier-supplied | 0 | PASS |
| AX-2026-041761 | CJC-1295 (no DAC) | FGP | FGP-2601-V1242 | 2026-Q2 | 99.93 | 6.74 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041351 | BPC-157 | WWB | WWB-2604-B3510 | 2026-Q2 | 99.93 | 5.75 | 91.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043373 | BPC-157 | CPC | CPC-2601-M2514 | 2026-Q2 | 98.49 | 6.54 | 105.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043273 | Hexarelin | CPC | CPC-2511-F1491 | 2026-Q2 | 98.28 | 4.57 | — | Supplier-supplied | 2 | FAIL |
| AX-2026-042863 | Retatrutide | GGPeps | GGPE-2601-C2423 | 2026-Q2 | 97.64 | 3.96 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042040 | Enclomiphene citrate | TFC | TFC-2605-H7009 | 2026-Q2 | 99.93 | 4.57 | 97.2 | Supplier-supplied | 0 | FAIL |
| AX-2026-041355 | BPC-157 | WWB | WWB-2604-B3510 | 2026-Q2 | 99.87 | 5.02 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043371 | BPC-157 | CPC | CPC-2601-M2514 | 2026-Q2 | 98.23 | 6.47 | 92.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043294 | IGF-1 LR3 | CPC | CPC-2512-S2394 | 2026-Q2 | 97.49 | 2.21 | 106.2 | Supplier-supplied | 0 | PASS |
| AX-2026-043293 | IGF-1 LR3 | CPC | CPC-2512-S2394 | 2026-Q2 | 97.85 | 2.41 | 95.2 | Supplier-supplied | 0 | PASS |
| AX-2026-042905 | Semax | MKM | MKM-2512-B2992 | 2026-Q2 | 99.04 | 6.55 | 98.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042785 | Selank | GGPeps | GGPE-2601-J1391 | 2026-Q2 | 99.93 | 9.81 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042748 | N-Acetyl Semax Amide | GGPeps | GGPE-2512-A1206 | 2026-Q2 | 98.71 | 7.41 | 93.3 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042621 | KPV | GGPeps | GGPE-2511-K8830 | 2026-Q2 | 98.74 | 5.02 | 99.7 | Supplier-supplied | 1 | FAIL |